The Aftermath of a 'Miracle Cure' for a Rare Cancer

In 2001, Gleevec was approved as a treatment for chronic myelogenous leukemia. It was a revelation for personalized medicine—with harrowing financial repercussions that persist today.

from Wired https://ift.tt/9BENlwn

Comments

Popular posts from this blog

Tableau launches new enterprise plans, big data tools

CanvasChamp is the perfect way to transform your home in the new year

KLH Launches Premium Sound at Affordable Prices